Involvement of P2X7 receptor signaling on regulating the differentiation of Th17 cells and type II collagen-induced arthritis in mice

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Fan, Zhi Dan ^a   Zhang, Ya Yuan ^a   Guo, Yi Hong ^a   Huang, Na ^a   Ma, Hui Hui ^a   Huang, Hui ^a   Yu, Hai Guo ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 2; CYTOKINE; P2XR RECEPTOR, HUMAN; PURINERGIC P2X RECEPTOR ANTAGONIST; PURINERGIC P2X7 RECEPTOR;

ANIMAL; CASE CONTROL STUDY; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CHEMICALLY INDUCED; CHILD; CYTOLOGY; DBA MOUSE; EXPERIMENTAL ARTHRITIS; FEMALE; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; MALE; METABOLISM; PATHOLOGY; TH17 CELL;

ANIMALS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, JUVENILE; CASE-CONTROL STUDIES; CD4-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CHILD; COLLAGEN TYPE II; CYTOKINES; FEMALE; HUMANS; MALE; MICE, INBRED DBA; PURINERGIC P2X RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2X7; TH17 CELLS;

EID: 84992187852     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep35804     Document Type: Article

References (72)

1. Firestein, G. S. Immunologic mechanisms in the pathogenesis of rheumatoid arthritis. J. Clin. Rheumatol. 11, S39-S44 (2005).
2. Gabriel, S. E. The epidemiology of rheumatoid arthritis. Rheum. Dis. Clin. North. Am. 27, 269-281 (2001).
3. Silber, J. S., Verma, R. B. & Greenberg, A. S. Rheumatoid arthritis of the cervical spine. Neurosurg. Q. 16, 1-8 (2006).
4. Fukase, M., Koizumi, F. & Wakaki, K. Histopathologic analysis of 16 subcutaneous rheumatoid nodules. Acta. Pathol. Jpn. 30, 871-882 (1980).
5. Radner, H. et al. Development of a multimorbidity index: Impact on quality of life using a rheumatoid arthritis cohort. Semin. Arthritis. Rheum. 45, 167-173 (2015).
6. Hromadkova, L., Soukup, T. & Vlcek, J. Quality of life and drug compliance: their interrelationship in rheumatic patients. J. Eval. Clin. Pract. 21, 919-924 (2015).
7. Lee, M. Y. et al. Cost-effectiveness of tofacitinib in the treatment of moderate to severe rheumatoid arthritis in South Korea. Clin. Ther. 37, 1662-1676 (2015).
8. Magyari, L. et al. Interleukins and interleukin receptors in rheumatoid arthritis: Research, diagnostics and clinical implications. World. J. Orthop. 5, 516-536 (2014).
9. Smolen, J. S. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological diseasemodifying antirheumatic drugs: 2013 update. Ann. Rheum. Dis. 73, 492-509 (2014).
10. Fournier, C. Where do T cells stand in rheumatoid arthritis? Joint Bone Spine 72, 527-532 (2005).
11. Alunno, A. et al. Altered immunoregulation in rheumatoid arthritis: the role of regulatory T cells and proinflammatory Th17 cells and therapeutic implications. Mediators Inflamm. 2015, 751793 (2015).
12. Paulissen, S. M., van Hamburg, J. P., Dankers, W. & Lubberts, E. The role and modulation of CCR6+ Th17 cell populations in rheumatoid arthritis. Cytokine 74, 43-53 (2015).
13. Pap, T., M�ller-Ladner, U., Gay, R. E. & Gay, S. Fibroblast biology. Role of synovial fibroblasts in the pathogenesis of rheumatoid arthritis. Arthritis. Res. 2, 361-367 (2000).
14. Furst, D. E. & Emery, P. Rheumatoid arthritis pathophysiology: update on emerging cytokine and cytokine-associated cell targets. Rheumatology (Oxford) 53, 1560-1569 (2014).
15. McInnes, I. B. & Schett, G. The pathogenesis of rheumatoid arthritis. N. Engl. J. Med. 365, 2205-2219 (2011).
16. Ferraccioli, G. & Zizzo, G. The potential role of Th17 in mediating the transition from acute to chronic autoimmune inflammation: rheumatoid arthritis as a model. Discov. Med. 11, 413-424 (2011).
17. Cheung, P. F., Wong, C. K. & Lam, C. W. Molecular mechanisms of cytokine and chemokine release from eosinophils activated by IL-17A, IL-17F, and IL-23: implication for Th17 lymphocytes-mediated allergic inflammation. J. Immunol. 180, 5625-5635 (2008).
18. Lubberts, E. et al. IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NFkappa B ligand/osteoprotegerin balance. J. Immunol. 170, 2655-2662 (2003).
19. Stagg, J. & Smyth M. J. Extracellular adenosine triphosphate and adenosine in cancer. Oncogene 29, 5346-5358 (2010).
20. Lopez-Castejon, G. et al. P2X(7) receptor-mediated release of cathepsins from macrophages is a cytokine-independent mechanism potentially involved in joint diseases. J. Immunol. 185, 2611-2619 (2010).
21. Baroja-Mazo, A. & Pelegr�n, P. Modulating P2X7 receptor signaling during rheumatoid arthritis: new therapeutic approaches for bisphosphonates. J. Osteoporos. 2012, 408242 (2012).
22. Sallusto, F., Zielinski, C. E. & Lanzavecchia, A. Human Th17 subsets. Eur. J. Immunol. 42, 2215-2220 (2012).
23. Acosta-Rodriguez, E. V., Napolitani, G., Lanzavecchia, A. & Sallusto, F. Interleukins 1beta and 6 but not transforming growth factorbeta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat. Immunol. 8, 942-949 (2007).
24. Wang, L. et al. Up-regulation of Th17 cells may underlie inhibition of Treg development caused by immunization with activated syngeneic T cells. PLoS One 6, e27289 (2011).
25. Wang, L. et al. Immunization with autologous T cells enhances in vivo anti-tumor immune responses accompanied by up-regulation of GADD45beta. Cell Res. 16, 702-712 (2006).
26. Fan, Z. D. et al. Artificial microRNA interference targeting AT(1a) receptors in paraventricular nucleus attenuates hypertension in rats. Gene Ther. 19, 810-817 (2012).
27. Elshabrawy, H. A., Coughlin, M. M., Baker, S. C. & Prabhakar, B. S. Human monoclonal antibodies against highly conserved HR1 and HR2 domains of the SARS-CoV spike protein are more broadly neutralizing. PLoS One 7, e50366 (2012).
28. Elshabrawy, H. A. et al. Identification of a broad-spectrum antiviral small molecule against severe acute respiratory syndrome coronavirus and Ebola, Hendra, and Nipah viruses by using a novel high-throughput screening assay. J. Virol. 88, 4353-4365 (2014).
29. Jung, E. G. et al. Anti-inflammatory activity of sappanchalcone isolated from Caesalpinia sappan L. in a collagen-induced arthritismouse model. Arch. Pharm. Res. 38, 973-983 (2015).
30. Pongratz, G., Melzer, M. & Straub, R. H. The sympathetic nervous system stimulates anti-inflammatory B cells in collagen-type IIinduced arthritis. Ann. Rheum. Dis. 71, 432-439 (2012).
31. Hu, J. et al. U87MG glioma cells overexpressing IL-17 acclerate early-stage growth in vivo and cause a higher level of CD31 mRNA expression in tumor tissues. Oncol. Lett. 6, 993-999 (2013).
32. Kim, S. J. et al. Identification of a novel Toll-like receptor 7 endogenous ligand in rheumatoid arthritis synovial fluid that can provoke arthritic joint inflammation. Arthritis Rheumatol. 68, 1099-1110 (2016).
33. Li, R. et al. Therapeutic effect of 7,3′-dimethoxy hesperetin on adjuvant arthritis in rats through inhibiting JAK2-STAT3 signal pathway. Int. Immunopharmacol. 14, 157-163 (2012).
34. Idzko, M. et al. Extracellular ATP triggers and maintains asthmatic airway inflammation by activating dendritic cells. Nat. Med. 13, 913-919 (2007).
35. Wiley, J. S., Sluyter, R., Gu, B. J., Stokes, L. & Fuller, S. J. The human P2X7 receptor and its role in innate immunity. Tissue Antigens 78, 321-332 (2011).
36. Ryan, L. M., Rachow, J. W. & McCarty, D. J. Synovial fluid ATP: a potential substrate for the production of inorganic pyrophosphate. J. Rheumatol. 18, 716-720 (1991).
37. Portales-Cervantes, L. et al. Expression and function of the P2X(7) purinergic receptor in patients with systemic lupus erythematosus andrheumatoid arthritis. Hum. Immunol. 71, 818-825 (2010).
38. Labasi, J. M. et al. Absence of the P2X7 receptor alters leukocyte function and attenuates an inflammatory response. J. Immunol. 168, 6436-6445 (2002).
39. Suadicani, S. O., Brosnan, C. F. & Scemes, E. P2X7 receptors mediate ATP release and amplification of astrocytic intercellular Ca2+ signaling. J. Neurosci. 26, 1378-1385 (2006).
40. Brandao-Burch, A., Key, M. L., Patel, J. J., Arnett, T. R. & Orriss, I. R. The P2X7 receptor is an important regulator of extracellular ATP levels. Front Endocrinol (Lausanne) 3, 41 (2012).
41. Pellegatti, P., Falzoni, S., Donvito, G., Lemaire, I. & Di Virgilio, F. P2X7 receptor drives osteoclast fusion by increasing the extracellular adenosine concentration. FASEB. J. 25, 1264-1274 (2011).
42. Brand, D. D., Latham, K. A. & Rosloniec, E. F. Collagen-induced arthritis. Nat. Protoc. 2, 1269-1275 (2007).
43. Kim, H. Y. et al. Enhanced T cell proliferative response to type II collagen and synthetic peptide CII (255-274) in patients with rheumatoid arthritis. Arthritis Rheum. 42, 2085-2093 (1999).
44. Londei, M. et al. Persistence of collagen type II-specific T-cell clones in the synovial membrane of a patient with rheumatoid arthritis. Proc. Natl. Acad. Sci. USA 86, 636-640 (1989).
45. Terato, K. v. Specificity of antibodies to type II collagen in rheumatoid arthritis. Arthritis Rheum. 33, 1493-1500 (1990).
46. Barber�-Cremades, M. et al. P2X7 receptor-stimulation causes fever via PGE2 and IL-1β release. FASEB. J. 26, 2951-2962 (2012).
47. Arulkumaran, N., Unwin, R. J. & Tam, F. W. A potential therapeutic role for P2X7 receptor (P2X7R) antagonists in the treatment of inflammatory diseases. Expert Opin. Investig. Drugs 20, 897-915 (2011).
48. Brandao-Burch, A., Key, M. L., Patel, J. J., Arnett, T. R. & Orriss, I. R. The P2X7 receptor is an important regulator of extracellular ATP levels. Front Endocrinol. 3, 41 (2012).
49. Schulze-Lohoff, E. et al. Extracellular ATP causes apoptosis and necrosis of cultured mesangial cells via P2Z/P2X7 receptors. Am. J. Physiol. 275, 962-971 (1998).
50. Vergani, A. et al. Long-term heart transplant survival by targeting the ionotropic purinergic receptor P2X7. Circulation 127, 463-475 (2013).
51. Sullivan, J. A. et al. Differential requirement for P2X7R function in IL-17 dependent vs. IL-17 independent cellular immune responses. Am. J. Transplant. 14, 1512-1522 (2014).
52. Killeen, M. E., Ferris, L., Kupetsky, E. A., Jr. Falo, L. & Mathers, A. R. Signaling through purinergic receptors for ATP induces human cutaneous innate and adaptive Th17 responses: implications in the pathogenesis of psoriasis. J. Immunol. 190, 4324-4336 (2013).
53. Shieh, C. H., Heinrich, A., Serchov, T., van Calker, D. & Biber, K. P2X7-dependent, but differentially regulated release of IL-6, CCL2, and TNF-α in cultured mouse microglia. Glia 62, 592-607 (2014).
54. Miller, C. M. et al. Dysregulation of the inflammatory response to the parasite, Toxoplasma gondii, in P2X7 receptor-deficient mice. Int. J. Parasitol. 41, 301-308 (2011).
55. Fazal, N. OX62+ OX6+ OX35+ rat dendritic cells are unable to prime CD4+ T cells for an effective immune response following acute burn injury. Results Immunol. 3, 64-72 (2013).
56. Baroja-Mazo, A. & Pelegr�n, P. Modulating P2X7 receptor signaling during rheumatoid arthritis: new therapeutic approaches for bisphosphonates. J. Osteoporos. 2012, 408242 (2012).
57. Yu, J. et al. Paeoniflorin down-regulates ATP-induced inflammatory cytokine production and P2X7R expression on peripheral blood mononuclear cells from patients with primary Sj�gren's syndrome. Int. Immunopharmacol. 28, 115-120 (2015).
58. Pellegatti, P., Falzoni, S., Pinton, P., Rizzuto, R. & Di Virgilio, F. A novel recombinant plasma membrane-targeted luciferase reveals a new pathway for ATP secretion. Mol. Biol. Cell 16, 3659-3665 (2005).
59. Schneider, E. M., Vorlaender, K., Ma, X., Du, W. & Weiss, M. Role of ATP in trauma-associated cytokine release and apoptosis by P2X7 ion channel stimulation. Ann. N. Y. Acad. Sci. 1090, 245-252 (2006).
60. Karmakar, M., Katsnelson, M. A., Dubyak, G. R. & Pearlman, E. Neutrophil P2X7 receptors mediate NLRP3 inflammasomedependent IL-1β secretion in response to ATP. Nat. Commun. 7, 10555 (2016).
61. Wang, C. M., Chang, Y. Y. & Sun, S. H. Activation of P2X7 purinoceptor-stimulated TGF-beta 1 mRNA expression involves PKC/ MAPK signallingpathway in a rat brain-derived type-2 astrocyte cell line, RBA-2. Cell Signal. 15, 1129-1137 (2003).
62. Xu, H. et al. High fatty acids modulate P2X(7) expression and IL-6 release via the p38 MAPK pathway in PC12 cells. Brain Res. Bull. 94, 63-70 (2013).
63. Schlegel, P. M., Steiert, I., K�tter, I. & M�ller, C. A. B cells contribute to heterogeneity of IL-17 producing cells in rheumatoid arthritis and healthy controls. PLoS One 8, e82580 (2013).
64. Bermejo, D. A. et al. Trypanosoma cruzi trans-sialidase initiates a program independent of the transcription factors RORγ t and Ahr that leads to IL-17 production by activated B cells. Nat. Immunol. 14, 514-522 (2013).
65. Pippel, A., Be�ler, B., Klapperst�ck, M. & Markwardt, F. Inhibition of antigen receptor-dependent Ca(2+ ) signals and NF-AT activation by P2X7 receptors in human B lymphocytes. Cell Calcium 57, 275-289 (2015).
66. Bhattacharya, P. et al. Dual role of GM-CSF as a pro-Inflammatory and a regulatory cytokine: implications for immune therapy. J. Interferon Cytokine Res. 35, 585-599 (2015).
67. Bhattacharya, P. et al. GM-CSF: An immune modulatory cytokine that can suppress autoimmunity. Cytokine 75, 261-271 (2015).
68. Gangi, E., Vasu, C., Cheatem, D. & Prabhakar, B. S. IL-10-producing CD4+ CD25+ regulatory T cells play a critical role in granulocyte-macrophage colony-stimulating factor-induced suppression of experimental autoimmune thyroiditis. J. Immunol. 174, 7006-7013 (2005).
69. Gathungu, G. et al. Granulocyte-macrophage colony-stimulating factor autoantibodies: a marker of aggressive Crohn's disease. Inflamm. Bowel Dis. 19, 1671-1680 (2013).
70. Rowin, J. et al. Granulocyte macrophage colony-stimulating factor treatment of a patient in myasthenic crisis: effects on regulatory T cells. Muscle Nerve 46, 449-453 (2012).
71. Farooq, S. M., Kumar A. & Ashour, H. M. Eye-mediated immune tolerance to Type II collagen in arthritis-prone strains of mice. J. Cell Mol. Med. 18, 2512-2518 (2014).
72. Farooq, S. M. & Ashour, H. M. Type II collagen induces peripheral tolerance in BALB/c mice via the generation of CD8+ T regulatory cells. PLoS One 7, e48635 (2012).